$TAUG Signs MOU to Sell and Distribute Natural Wellness Products in Asia

LOS ANGELES, Nov. 4, 2014 (GLOBE NEWSWIRE) — Tauriga Sciences, Inc. (TAUG) or (“Tauriga” or the “Company”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that it has signed a non-binding MOU with Japan-based iFlow, Ltd. (“iFlow”) to distribute and sell three new Tauriga-branded natural wellness products to the Japan, Taiwan and Hong Kong regions (the “Territory”). iFlow is an innovative and entrepreneurial Asian marketing and distribution company with motivational products in health, lifestyle, education, business and finance. If a definitive agreement is reached, the partnership between the companies would enable Tauriga to reach Asian customers with an interest in natural healing. The intent of the parties is for the initial focus of the partnership to be on two different formulations of Tauriga’s proprietary TopiCanna topical cannabis cream and on Tauriga’s CannaCaviar brand of small soft gel supplements. In compliance with Japanese medical marijuana law, all three products would use oil that has been extracted from the stalk of the cannabis plant and that is higher in CBD (cannabidiol) and low in THC, hence providing wellness and healing properties without psychoactive effects. If the initial phase of the proposed partnership is successful in establishing the Tauriga natural wellness brand in the Territory, the two companies plan to extend the agreement to include additional Tauriga products, such as Tauriga’s new line of natural dietary supplements.

Tauriga’s Chairman & CEO Dr. Stella M. Sung commented, “iFlow has built an extensive network of consumers in Asia who are passionate about improving their quality of life in organic and natural ways. We believe that there is a strong and growing demand for Tauriga’s TopiCanna creams and CannaCaviar soft gel supplements. Our potential partnership with iFlow would allow us to quickly establish the Tauriga brand in Japan as we focus on creating and building recurrent revenue streams.”

In late September, Tauriga announced that it had restructured its Honeywood transaction into a License and Supply Agreement which provides Tauriga access to the Doc Green’s topical cannabis cream and future products. In addition, Tauriga Sciences owns unique formulations of cannabis cream it began developing while working with Honeywood, including Tauriga’s new TopiCanna line of topical cannabis creams for different healing properties. Tauriga has also launched Cannabis Complements, the Company’s own line of natural dietary supplements that address cannabis-related effects but that do not contain cannabis oil. Flagship products include IndiCalm, a relaxant and anxiolytic based on L-theanine; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant; and EndoCannabinoid Omega-3 Support (or MendCan), a highly pure, potent and palatable Omega 3 supplement.

Tauriga’s Chief Medical Officer Lawrence A. May, M.D. added, “Through the potential partnership with iFlow, we would be able to begin to provide effective natural health remedies on a global scale, promote wellness and start to build a profitable, sustainable patient- and consumer-centered business.”

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com.

NON SOLICITATION:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

Tauriga Sciences, Inc.:
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
www.tauriga.com
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697
Email: ssung@tauriga.com